Skip to content
value.today
Sunshine Biopharma, Inc. logo

Sunshine Biopharma, Inc.

SBFM
$3 Mmarket cap on Oct 30, 2026-60.9% since Jan 2024
Compare
World rank
#27,570
Revenue
$36 M
For year ending December-2025
Net income
$-6 M
-16.5% margin
SEC filing
Employees
50
As of December 31, 2025
SEC filing

Sunshine Biopharma, Inc. in brief

Sunshine Biopharma, Inc. is a listed company in the Pharmaceutical industry, based in Montreal, Canada. Its market value was $3 M on 30 October 2026, which makes it the 27,570th largest listed company in the world and the 1,751st largest in Canada on this site. In the year to December 2025 it had sales of $36 M and a net loss of $6 M. It employs about 50 people. Its shares trade under the symbol SBFM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Sunshine Biopharma, Inc.

We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation, through which we currently have 71 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation which develops and sells OTC supplements.

In addition, we are conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and (ii) SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections.

From the company's annual report filed with the US SEC: read the report

Sunshine Biopharma, Inc. timeline

4 events, 2007–2025
  1. 2007
  2. ✎
    Renamed mountain west business solutions,inc
    Formerly mountain state business solutions,inc.
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2009
  5. ✎
    Renamed Sunshine Biopharma, Inc
    Formerly mountain west business solutions,inc.
  6. 2025
  7. 💰
    Record revenue of $36 million
    FY2025, the highest of the 7 years on record.

Events of Sunshine Biopharma, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$9 M$18 M$27 M$36 M2023202420252026

World rank over time

▲ up 1,147 places since 2022
2022-01-07: #28724#28,72420222022-12-25: #30412#30,41220222023-07-30: #31059#31,05920232024-01-05: #31887#31,88720242026-03-08: #13142#13,14220262026-08-01: #24081#24,08120262026-10-30: #27577#27,5772026

Rank in Canada: #1,124 (Jan 2022) · #1,198 (Dec 2022) · #1,197 (Jul 2023) · #1,375 (Jan 2024) · #55 (Mar 2026) · #837 (Aug 2026) · #1,751 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.1×
Price / book
0.1×
Free cash flow yield
-200.7%
Net margin (TTM)
-17.4%
Operating margin
-17.2%
Return on equity
-26.8%
Liabilities / assets
23.4%
Net debt
$-0M
Revenue growth
+4.1%
R&D / revenue
1.7%
Revenue per employee
$726 K
Profit per employee
$-120 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-2M—FY18Fiscal year ending Dec 2019: revenue $0M, net income $-2M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-3M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-12M$0MFY21Fiscal year ending Dec 2022: revenue $4M, net income $-27M$4MFY22Fiscal year ending Dec 2023: revenue $24M, net income $-5M$24MFY23Fiscal year ending Dec 2024: revenue $35M, net income $-5M$35MFY24Fiscal year ending Dec 2025: revenue $36M, net income $-6M$36MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$36M+4.1%$-6M$-6M-16.5%
Dec 2024$35M+44.7%$-6M$-5M-14.7%
Dec 2023$24M+453.8%$-5M$-5M-18.7%
Dec 2022$4M+1791.3%$-27M$-27M-614.7%
Dec 2021$0M+228.6%$-2M$-12M-5408.7%
Dec 2020$0M+250.0%$-1M$-3M-3971.4%
Dec 2019$0M—$-1M$-2M-8300.0%
Dec 2018——$-1M$-2M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$0M$-6M——
Dec 2024$-13M$2M$-14M$-7.32—
Dec 2023$-9M$0M$-9M$-351.36—
Dec 2022$-5M$0M$-5M$-1.76—
Dec 2021$-2M$0M$-2M$-4.76—
Dec 2020$-1M$0M$-1M——
Dec 2019$-1M$0M$-1M——
Dec 2018$-1M$0M$-1M——

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$35M
Net income, trailing 12 months
$-6M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $10M, net income $-2M$10MDec ’24Three months to Mar 2025: revenue $9M, net income $-1M$9MMar ’25Three months to Jun 2025: revenue $9M, net income $-2M$9MJun ’25Three months to Sep 2025: revenue $9M, net income $-1M$9MSep ’25Three months to Dec 2025 (from the annual report): revenue $9M, net income $-2M$9MDec ’25Three months to Mar 2026: revenue $8M, net income $-1M$8MMar ’26Three months to Jun 2026: revenue $9M, net income $-2M$9MJun ’26Three months to Sep 2026: revenue $9M, net income $-1M$9MSep ’26

Latest quarter to Sep 2026: revenue $9M (+0.2% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Sunshine Biopharma, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$36 M
Operating income
$-6 M
Net income
$-6 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$30 M
Total liabilities
$7 M
Total equity
$23 M

As of December-2025

Top 15 institutional investors in Sunshine Biopharma, Inc.#

As of Sep 30, 2026
15 institutions held 157,698 shares (about 19.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 19.1%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 15 largest institutional investors in Sunshine Biopharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Jane Street Group, LLC60,309+45,335 (+302.76%)7.32%$0 MNov 12, 2026
2UBS Group AG34,715New4.21%$0 MNov 10, 2026
3Virtu Financial LLC22,216New2.70%$0 MNov 17, 2026
4XTX Topco Ltd20,157New2.45%$0 MNov 16, 2026
5Susquehanna International Group, LLP18,397New2.23%$0 MNov 16, 2026
6Pinnacle Financial Group, Inc.1,200—0.15%$0 MNov 16, 2026
7Morgan Stanley3850 (0.00%)0.05%$0 MNov 13, 2026
8SBI Securities Co., Ltd.213+51 (+31.48%)0.03%$0 MOct 22, 2026
9Caitong International Asset Management Co., Ltd50+49 (+4900.00%)0.01%$0 MOct 29, 2026
10Robinhood Markets, Inc.39—0.00%$0 MNov 18, 2026
11Jpmorgan Chase & Co8New0.00%$0 MNov 12, 2026
12National Bank Of Canada /fi/50 (0.00%)0.00%$0 MNov 16, 2026
13Osaic Holdings, Inc.20 (0.00%)0.00%$0 MNov 12, 2026
14TD Waterhouse Canada Inc.10 (0.00%)0.00%$0 MOct 16, 2026
15Strive Financial Group ,LLC10 (0.00%)0.00%$0 MNov 9, 2026

Insider trading at Sunshine Biopharma, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
5
since
$10 K$0Feb 2024: bought $2 K (1 trades), sold $0 (0 trades)Feb 24Mar 2024: bought $10 K (1 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Sunshine Biopharma, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David NatanDirectorGrant or award+58,300——68,300Form 4
filed David NatanDirectorGrant or award+100,000——100,000Form 4
filed Steve N. SlilatyChief Executive Officer, Director, 10% ownerBuy+100,000$0.100$10 K130,000Form 4
filed Steve N. SlilatyChief Executive Officer, Director, 10% ownerBuy+20,000$0.100$2 K30,000Form 4
filed Camille SebaalyCFO/SecretaryBuy+30,000$0.760$23 K174,465Form 4
filed Camille SebaalyCFO/SecretaryBuy+25,000$1.220$31 K144,465Form 4
filed Steve N. SlilatyChief Executive Officer, DirectorDisposal to the company-990,000$0.100$99 K10,000Form 4
filed Camille SebaalyCFO/Secretary, DirectorGrant or award+20.00 M——23.89 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Sunshine Biopharma, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
176,303
1.03 days to cover
Buybacks, Q4 2025
$0M
Q4 2025
Reg SHO threshold list
17 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →
Sunshine Biopharma, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2025Q4 2025$0M
Q3 2025Q3 2025$0M
Q2 2025Q2 2025$0M
Q1 2025Q1 2025$0M
Q4 2024Q4 2024$0M
Q3 2024Q3 2024$0M
Q2 2024Q2 2025$0M
Q1 2024Q1 2025$3.1M
Q4 2023Q4 2024$0M

Trading halts

  • 2026-10-23 23:50 UTC, code T3, resumed 13:00 UTC
  • 2026-10-07 15:59 UTC, code LUDP, resumed 16:04 UTC
  • 2026-10-07 15:37 UTC, code LUDP, resumed 15:42 UTC
  • 2026-10-07 15:30 UTC, code LUDP, resumed 15:35 UTC
  • 2026-10-07 15:25 UTC, code LUDP, resumed 15:30 UTC

Fails to deliver

  • : 921 shares at $3.33
  • : 10,080 shares at $3.11
  • : 40,087 shares at $2.96
  • : 15,815 shares at $2.65
  • : 79,833 shares at $0.24

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Sunshine Biopharma, Inc. scorecard#

Passes 8 of the 18 checks that could be worked out: strongest in growth (4 of 5), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.1×Price to book 0.1× against Pharmaceutical's median of 3.2×.
    • ✓Price to sales below its peers' median0.1×Price to sales 0.1× against Pharmaceutical's median of 3.5×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • ✓Revenue grew in the newest year4.1%Revenue up 4.1% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years102.8%102.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median102.8%102.8% a year against Pharmaceutical's median of 2.5% (65 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$3 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-17.2%-17.2% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-25.7%-25.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-17.2%-17.2% in fiscal 2025 against -620.7% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities4.2×Current ratio 4.17 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-1.92Z-score -1.92 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Sunshine Biopharma, Inc.'s statements, beside the median of Pharmaceutical.

Sunshine Biopharma, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-17.2%1.8%
Net margin-16.5%-1.5%
Return on equity-25.7%-0.9%
Revenue growth, 3 years a year102.9%2.5%
Revenue growth4.1%7.3%
Free cash flow margin-15.2%6.0%

5of 8on the Piotroski tests of financial strength

  • Net loss of $6 million, the 16th loss-making year in a row.
  • Free cash flow was negative: -$6 million.
  • Revenue has grown 6 years in a row.

Sunshine Biopharma, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Sunshine Biopharma, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue36,30634,87424,0934,34622871210r00
Cost of revenue24,05024,20415,7542,64911826110r0—
Gross profit12,25610,6708,3391,69711146100r0—
Research and development6049341,8568126721.7r1513033
General and administrative18,48316,48213,12428,6972,5516226521,164r857993
Operating income−6,227−5,812−4,785−27,001−2,440−577−642−1,164r−857−993
Interest expense and finance costs08.813739329168116143r10535
Other non-operating income (expense)273443674490−9,996−2,207−436−974r−183−2,504
Income before tax−5,954−5,369−4,111−26,511−12,436—————
Income tax22−23539523300————
Income from continuing operations—————−2,784−1,078−2,138——
Income from discontinued operations—————0−582−18——
Net income including minority interests————−12,457−2,784r−1,660−2,156r−1,040−3,497r
Net income attributable to shareholders−5,975−5,134−4,506−26,744−12,436−2,784−1,660−2,156−1,040−3,497
Earnings per share, basic-1.44-7.32-351.36r-1.76-4.76-2.73r-0.15-0.71r-0.02r-0.01
Earnings per share, diluted—-7.32-351.36r-1.76-4.76—————
Shares, weighted average (basic)4.20.70.0r152.61.0r113.0r44r425
Shares, weighted average (diluted)—0.70.0r152.6—————
Balance sheet
Cash and cash equivalents9,1239,68716,29221,8262,04599041111r10857
Receivables3,4603,8682,5521,9127.81.90.40r0—
Inventory13,47211,2785,7353,29010624160——
Other current assets—————2.81.31.39.71.0
Current assets26,85425,96624,89027,3122,1961,026661,101r11758
Property, plant and equipment5575463663947.1203245r605.9
Right-of-use (leased) assets7799366477600——0——
Goodwill—0000—6666660—
Other intangible assets1,8893,0201,444777000000
Non-current assets3,2264,5942,457——20—935——
Total assets30,07930,56027,34729,2442,2031,045981,14725764
Accounts payable5,6645,5432,5852,803r436397116r1928
Current liabilities6,4446,3155,5526,931911,051834912751274
Lease liabilities (non-current)5977455396420——0——
Non-current liabilities5977455886851,900——290——
Total liabilities7,0417,0606,1407,6161,9912,0008341,202831274
Retained earnings−75,015−69,040−63,906−59,400−32,655−20,219−17,435−15,774−13,618−12,578
Shareholders' equity23,03823,50121,20721,628212−955−735−56−573r−210
Total liabilities and equity30,07930,56027,34729,2442,2031,045981,14725764
Shares outstanding0.0r2.60.0r232.61.7r354.3r46r769
Cash-flow statement
Depreciation and amortization33222414925131414496.661
Share-based compensation—————272277755520499r
Cash from operating activities−5,331−12,525r−8,775−5,248−1,829−657−496−513−544−314
Capital expenditure−174−1,657−82−1940−1.2−0.9−19−3.7−3.4
Intangible assets bought−662−322−706−1110————0
Cash from investing activities−836−1,979r−656−14,6190−1.2−15−14−84−3.4
Shares issued1,8298,5224,08930,3670——064104
Shares bought back0−3,140−541———————
Cash from financing activities4,7488,942r3,42639,4652,9051,608442528671325
Exchange-rate effect on cash—0−63−1.10r−0.4−5.96.86.9−0.3
Change in cash—————950−690.9437.0
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Sunshine Biopharma, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Sunshine Biopharma, Inc.: countries of operation
CountryPresenceRevenue there
🇨🇦 CanadaHeadquarters—
🇺🇸 USA1 office—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Sunshine Biopharma, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$466 K
Dr. Steve N. Slilaty
Other top executives, average
$960 K
the CEO earned 0.5× this
$100 invested is now
$0
Sunshine Biopharma, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Steve N. Slilaty$466 K$466 K$960 K$0
2024Dr. Steve N. Slilaty$1.2 M$1.2 M$639 K$0
2023Dr. Steve N. Slilaty$560 K$560 K$955 K$0

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Sunshine Biopharma, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 3 · Material agreement 5 · Shareholder vote 6 · Results announced 4

Sunshine Biopharma, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Shareholder vote8-K
Auditor changed8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 14, 2026

Acquisitions and funding#

1 acquisitions, $19 M paid where reported

Businesses it acquired

Acquisitions by Sunshine Biopharma, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Nora Pharma2022—$19 M—Annual report

Private share sales · funding history

Private share sales of Sunshine Biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$5 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Apr 2022$20 MPrivate placement after listing$10 to $50 million9equity, optionsSEC
Mar 2022$8 MPrivate placement after listing$2 to $10 million9equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Sunshine Biopharma, Inc. compares in Pharmaceutical

  • Market cap$3 M · higher than 2% of 393
  • Revenue$36 M · higher than 12% of 324
  • Net margin-17.4% · higher than 15% of 313
  • Revenue growth4.1% · higher than 41% of 107
  • Price / sales0.1× · lower than 99% of 219
  • Price / book0.1× · lower than 99% of 207

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Sunshine Biopharma, Inc.🇨🇦$3 M—-17.4%+4.1%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Sunshine Biopharma, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Sunshine Biopharma, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Sunshine Biopharma, Inc.? Suggest a correction